• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29

    Adjusted EBITDA up 33% to $14.6 million

    LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026.

    First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter

    • Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).
    • Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.
    • GAAP net income attributable to common shareholders was $5.1 million, or $0.29 per diluted common share, compared to $4.7 million, or $0.25 per diluted common share.
    • Adjusted EBITDA was up 33% to $14.6 million compared to $11.0 million.

    Management Commentary

    "We delivered a strong start to 2026, reflecting continued momentum across our key strategic initiatives," said Ken Romanzi, CEO of Nature's Sunshine. "We generated sales growth across all regions, led by North America with 9% constant currency growth. Our digital channel continues to scale, with strong engagement from both new and returning consumers."

    "Our first quarter performance underscores our focus on disciplined execution: strengthening consumer acquisition, expanding our digital capabilities, accelerating adoption of our auto ship subscription programs, and improving gross margin. As we look ahead, we are confident that the key strategies of our Vision for Growth will drive sustainable growth and long-term shareholder value."

    First Quarter 2026 Financial Results

      Net Sales by Operating Segment(Amounts in Thousands)
    Three Months Ended March 31,  2026  2025 Percent

    Change
     Impact of

    Currency

    Exchange
     Percent

    Change

    Excluding

    Impact of

    Currency
    Asia $52,183 $48,653 7.3% $663 5.9%
    Europe  26,395  24,114 9.5   839 6.0 
    North America  38,323  35,018 9.4   120 9.1 
    Latin America and Other  5,991  5,463 9.7   224 5.6 
      $122,892 $113,248 8.5% $1,846 6.9%
                    

    Net sales in the first quarter increased 9% to $122.9 million compared to $113.2 million in the same year-ago quarter. Excluding the impact from foreign exchange rates, net sales in the first quarter of 2026 increased 7% compared to the year-ago quarter.

    Gross profit margin in the first quarter increased to 73.2% compared to 72.1% in the year-ago quarter. The increase was driven by cost savings initiatives, market mix and favorable foreign exchange.

    Volume incentives as a percentage of net sales were 30.0% compared to 30.8% in the year-ago quarter. The decrease was primarily due to timing of promotional incentives and changes in product pricing and market mix.

    Selling, general and administrative expenses ("SG&A") in the first quarter were $43.5 million compared to $40.6 million in the year‐ago quarter. As a percentage of net sales, SG&A expenses were 35.4% for the first quarter of 2026 compared to 35.8% in the year-ago quarter. The decrease as a percentage of net sales was primarily related to reductions in professional fees, digital marketing and other non-recurring expenses.

    Operating income in the first quarter increased to $9.5 million, or 7.8% of net sales, compared to $6.2 million, or 5.4% of net sales, in the year-ago quarter.

    Other income (expense), net, in the first quarter of 2026 was expense of $1.4 million compared to income of $0.9 million in the first quarter of 2025. Other income (expense), net, primarily consisted of foreign exchange losses in Asia, Europe and Latin America that resulted from net changes in foreign currencies. The provision for income taxes was $3.0 million in the first quarter of 2026 compared to $2.2 million for the year-ago quarter.

    GAAP net income attributable to common shareholders increased to $5.1 million, or $0.29 per diluted common share, compared to $4.7 million, or $0.25 per diluted common share, in the first quarter of 2025. As a result of the December 2025 purchase of noncontrolling interests, there was no net income attributable to NSP China for the first quarter of 2026, compared to $0.7 million, or $0.04 per diluted common share, for the first quarter of 2025.

    Adjusted EBITDA in the first quarter increased 33% to $14.6 million compared to $11.0 million in the year-ago quarter. The increase was driven primarily by the increase in net sales. Adjusted EBITDA, which is a non-GAAP financial measure, is defined here as net income from continuing operations before taxes, depreciation, amortization, and other income (loss) adjusted to exclude share-based compensation expense and certain noted adjustments. A reconciliation of net income to adjusted EBITDA is provided in the attached financial tables.

    Balance Sheet and Cash Flow

    Net cash used by operating activities was $1.8 million for the three months ended March 31, 2026, compared to $2.6 million provided in the prior year period. Capital expenditures during the three months ended March 31, 2026, totaled $2.5 million compared to $1.1 million in the comparable period of 2025. During the three months ended March 31, 2026, the Company repurchased 20,000 shares at a total cost of $0.5 million, or $24.54 per share. As of March 31, 2026, the Company had cash and cash equivalents of $87.6 million and zero debt.

    Outlook

    Nature's Sunshine continues to expect 2026 net sales to range between $500 - $515 million and adjusted EBITDA to range between $50 - $54 million.

    Conference Call

    The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its first quarter of 2026 results.

    Date: Thursday, May 7, 2026

    Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)

    Toll-free dial-in number: 1-800-717-1738

    International dial-in number: 1-646-307-1865

    Conference ID: 28116

    Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

    The conference call will be broadcast live and available for replay here and via the Events section of the Nature's Sunshine website here.

    A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through Thursday, May 21, 2026.

    Toll-free replay number: 1-844-512-2921

    International replay number: 1-412-317-6671

    Replay ID: 1128116

    About Nature's Sunshine Products

    Nature's Sunshine Products (NASDAQ:NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature's Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety, and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvements in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:

    • failure to comply with laws and regulations relating to trade restrictions and export controls;
    • laws and regulations regarding direct selling that may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
    • current and potential future extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
    • registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
    • legal challenges to the Company's direct selling program or to the classification of its independent consultants;
    • failure of the Company's independent consultants to comply with advertising laws;
    • product liability claims;
    • impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
    • the Company's ability to attract and retain independent consultants;
    • the loss of one or more key independent consultants who have a significant sales network;
    • potential for liability relating to the Company's full ownership of China business;
    • the effect of fluctuating foreign exchange rates;
    • liabilities and obligations arising from improper activity by the Company's independent consultants;
    • changes to the Company's independent consultant compensation plans;
    • geopolitical issues, conflicts or other global events;
    • negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company's consumers to purchase products;
    • risks associated with the manufacturing of the Company's products;
    • supply chain disruptions, manufacturing interruptions or delays or the failure to accurately forecast consumer demand;
    • failure to timely and effectively obtain shipments of products from our suppliers and deliver products to our independent consultants and consumers;
    • uncertainties relating to the application of transfer pricing, duties, value-added taxes and other tax regulations, and changes thereto;
    • failure to maintain an effective system of internal controls over financial reporting;
    • cybersecurity threats and exposure to data loss;
    • the storage, processing and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
    • reliance on information technology infrastructure; and
    • the sufficiency of trademarks and other intellectual property rights.

    These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption "Risk Factors" in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

    All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.

    Non-GAAP Financial Measures

    We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income, adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.

    We utilize the non-GAAP measures of non-GAAP net income and adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance.

    Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature's Sunshine Products' performance in relation to other companies. We have included a reconciliation of net income to adjusted EBITDA, the most comparable GAAP measure. We have also included a reconciliation of GAAP net income to non-GAAP net income and non-GAAP adjusted EPS, in the attached financial tables.

    Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.

    We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

    With respect to our adjusted EBITDA outlook for the full year 2026, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

    Investor Relations:

    Gateway Group, Inc.

    Cody Slach

    1-949-574-3860

    NATR@gateway-grp.com

             
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (Amounts in thousands, except per share information)

    (Unaudited)
     
             
    Three Months Ended March 31,  2026   2025 
    Net sales $122,892  $113,248 
    Cost of sales  32,915   31,651 
    Gross profit  89,977   81,597 
         
    Operating expenses:    
    Volume incentives  36,893   34,844 
    Selling, general and administrative  43,539   40,581 
    Operating income  9,545   6,172 
    Other income (expense):    
    Interest and other income, net  74   205 
    Interest expense  (35)  (21)
    Foreign exchange (losses) gains, net  (1,429)  753 
       (1,390)  937 
    Income from operations before provision for income taxes  8,155   7,109 
    Provision for income taxes  3,037   2,225 
    Net income  5,118   4,884 
    Net income attributable to noncontrolling interests  —   137 
    Net income attributable to common shareholders $5,118  $4,747 
         
    Basic and diluted net income per common share:    
         
    Basic earnings per share attributable to common shareholders $0.29  $0.26 
         
    Diluted earnings per share attributable to common shareholders $0.29  $0.25 
         
    Weighted average basic common shares outstanding  17,522   18,486 
    Weighted average diluted common shares outstanding  17,929   18,846 



        
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)
        
     March 31,

    2026
     December 31,

    2025
    Assets   
    Current assets:   
    Cash and cash equivalents$87,578  $93,891 
    Accounts receivable, net of allowance for doubtful accounts of $63 and $69, respectively 12,549   8,602 
    Inventories 67,131   68,312 
    Prepaid expenses and other 11,330   8,040 
    Total current assets 178,588   178,845 
        
    Property, plant and equipment, net 31,413   32,915 
    Operating lease right-of-use assets 20,375   17,600 
    Restricted investment securities - trading 1,275   1,132 
    Deferred income tax assets 19,411   20,068 
    Other assets 10,396   10,586 
    Total assets$261,458  $261,146 
        
    Liabilities and Shareholders' Equity   
    Current liabilities:   
    Accounts payable$8,251  $8,021 
    Accrued volume incentives and service fees 25,611   22,624 
    Accrued liabilities 25,388   34,080 
    Deferred revenue 2,780   5,840 
    Income taxes payable 4,969   4,703 
    Current portion of operating lease liabilities 4,367   3,270 
    Total current liabilities 71,366   78,538 
        
    Liability related to unrecognized tax benefits 434   428 
    Long-term portion of operating lease liabilities 18,063   15,630 
    Deferred compensation payable 1,275   1,132 
    Deferred income tax liabilities 799   954 
    Other liabilities 2,605   2,911 
    Total liabilities 94,542   99,593 
        
    Commitments and contingencies   
        
    Shareholders' equity:   
    Common stock, no par value, 50,000 shares authorized, 17,564 and 17,508 shares issued and outstanding, respectively 102,252   102,192 
    Retained earnings 82,046   76,928 
    Accumulated other comprehensive loss (17,382)  (17,567)
    Total shareholders' equity 166,916   161,553 
    Total liabilities and shareholders' equity$261,458  $261,146 



             
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

    (Unaudited)
     
             
    Three Months Ended March 31,  2026   2025 
    CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net income $5,118  $4,884 
    Adjustments to reconcile net income to net cash provided (used) by operating activities:    
    Depreciation and amortization  3,224   3,499 
    Non-cash lease expense  1,008   1,479 
    Share-based compensation expense  1,639   1,300 
    Deferred income taxes  677   (1,982)
    Purchase of trading investment securities  (184)  (61)
    Proceeds from sale of trading investment securities  2   1 
    Realized and unrealized gains on investments  39   37 
    Foreign exchange (gains) losses  1,429   (753)
    Changes in assets and liabilities:    
    Accounts receivable  (4,094)  (1,786)
    Inventories  444   (5,053)
    Prepaid expenses and other current assets  (3,332)  (1,242)
    Other assets  (199)  (157)
    Accounts payable  1,003   644 
    Accrued volume incentives and service fees  3,179   1,986 
    Accrued liabilities  (8,735)  (1,116)
    Deferred revenue  (3,095)  (293)
    Lease liabilities  (245)  (1,502)
    Income taxes payable  127   2,283 
    Liability related to unrecognized tax benefits  6   418 
    Deferred compensation payable  143   23 
    Net cash provided (used) by operating activities  (1,846)  2,609 
    CASH FLOWS FROM INVESTING ACTIVITIES:    
    Purchases of property, plant and equipment  (2,480)  (1,110)
    Net cash used in investing activities  (2,480)  (1,110)
    CASH FLOWS FROM FINANCING ACTIVITIES:    
    Proceeds from revolving credit facility  11,621   735 
    Principal payments of revolving credit facility  (11,621)  (735)
    Payments related to tax withholding for net-share settled equity awards  (1,079)  (255)
    Repurchase of common stock  (500)  (476)
    Net cash used in financing activities  (1,579)  (731)
    Effect of exchange rates on cash and cash equivalents  (408)  1,018 
    Net increase (decrease) in cash and cash equivalents  (6,313)  1,786 
    Cash and cash equivalents at the beginning of the period  93,891   84,700 
    Cash and cash equivalents at the end of the period $87,578  $86,486 
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
    Cash paid for income taxes, net of refunds $2,375  $1,875 
    Cash paid for interest  35   15 



            
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

    (Amounts in thousands)

    (Unaudited)
     
            
    Three Months Ended March 31,  2026  2025 
    Net income $5,118 $4,884 
    Adjustments:    
    Depreciation and amortization  3,224  3,499 
    Share-based compensation expense  1,639  1,300 
    Other (income) expense, net*  1,390  (937)
    Provision for income taxes  3,037  2,225 
    Other adjustments (1)  173  — 
    Adjusted EBITDA $14,581 $10,971 
         
         
    (1) Other adjustments    
    Other non-recurring expenses $173 $— 
    Total adjustments $173 $— 

    * Other (income) loss, net is primarily comprised of foreign exchange (gains) losses, interest income, and interest expense.

            
    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    RECONCILIATION OF GAAP NET INCOME TO

    NON-GAAP NET INCOME and NON-GAAP ADJUSTED EPS

    (Amounts in thousands)

    (Unaudited)
            
    Three Months Ended March 31,  2026   2025
    Net income $5,118  $4,884
    Adjustments:    
    Other non-recurring expenses  173   —
    Tax impact of adjustments  (43)  —
    Total adjustments  130   —
    Non-GAAP net income $5,248  $4,884
         
    Reported income attributable to common shareholders $5,118  $4,747
    Total adjustments  130   —
    Non-GAAP net income attributable to common shareholders $5,248  $4,747
         
    Basic income per share, as reported $0.29  $0.26
    Total adjustments, net of tax  0.01   —
    Basic income per share, as adjusted $0.30  $0.26
         
    Diluted income per share, as reported $0.29  $0.25
    Total adjustments, net of tax  0.01   —
    Diluted income per share, as adjusted $0.30  $0.25





    Primary Logo

    Get the next $NATR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President, Asia Norman Daniel C sold $200,476 worth of shares (9,713 units at $20.64), decreasing direct ownership by 17% to 47,276 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    6/3/26 6:44:18 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Brower Nathan G sold $262,408 worth of shares (12,015 units at $21.84), decreasing direct ownership by 22% to 43,438 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    5/22/26 11:59:55 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fasching Steven J. was granted 4,500 shares, increasing direct ownership by 41% to 15,369 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    5/20/26 12:17:48 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    SEC Filings

    View All

    SEC Form S-8 filed by Nature's Sunshine Products Inc.

    S-8 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/15/26 4:52:47 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/11/26 8:46:55 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/7/26 5:19:52 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29Adjusted EBITDA up 33% to $14.6 million LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.GAAP net income attributable to common shareholders was $5.1

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer

    LEHI, Utah, April 30, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, today announced that John Hnanicek has been appointed Chief Technology Officer, effective May 4, 2026. Mr. Hnanicek brings decades of senior leadership experience in technology, digital innovation, and e-commerce transformation across leading consumer, retail, and direct-to-consumer organizations. He most recently served as Chief Digital Innovation Officer at Melaleuca, where he led enterprise-wide digital initiatives, technology modernization, and customer innova

    4/30/26 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 5:00 p.m. ET

    LEHI, Utah, April 23, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2026. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question-and-answer period. Date: Thursday, May 7, 2026Time: 5:00 p.m. Eastern

    4/23/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer

    LEHI, Utah, April 30, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, today announced that John Hnanicek has been appointed Chief Technology Officer, effective May 4, 2026. Mr. Hnanicek brings decades of senior leadership experience in technology, digital innovation, and e-commerce transformation across leading consumer, retail, and direct-to-consumer organizations. He most recently served as Chief Digital Innovation Officer at Melaleuca, where he led enterprise-wide digital initiatives, technology modernization, and customer innova

    4/30/26 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29Adjusted EBITDA up 33% to $14.6 million LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.GAAP net income attributable to common shareholders was $5.1

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 5:00 p.m. ET

    LEHI, Utah, April 23, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2026. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question-and-answer period. Date: Thursday, May 7, 2026Time: 5:00 p.m. Eastern

    4/23/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care